Global Non-Alcoholic Steatohepatitis Biomarkers Market Segments 2024, Forecast To 2033
5 Mar, 2024
The non-alcoholic steatohepatitis biomarkers market has shown exponential growth, increasing from $1.11 billion in 2023 to $1.39 billion in 2024, with a compound annual growth rate (CAGR) of 25.6%. This growth is attributed to diabetes and metabolic syndrome, awareness and screening programs, limitations of liver biopsy, regulatory support, and the shift towards personalized medicine, along with clinical trials in NASH. Looking ahead to 2028, the market is expected to reach $3.2 billion, maintaining a 23.1% CAGR. The forecasted growth is linked to the emergence of novel therapies, expansion of precision medicine approaches, patient advocacy initiatives, integration of multi-omics data, enhanced patient engagement, and telemedicine and remote monitoring.
Global Non-Alcoholic Steatohepatitis Biomarkers Market Key Driver
The non-alcoholic steatohepatitis biomarkers market is growing with the increasing prevalence of liver cancer. Hepatitis B virus is responsible for about 56% of liver cancer cases, driving the demand for biomarkers in early detection and monitoring.
Get A Free Sample Of The Global Non-Alcoholic Steatohepatitis Biomarkers Market ReportGlobal Non-Alcoholic Steatohepatitis Biomarkers Market Segments
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centres, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Non-Alcoholic Steatohepatitis Biomarkers Industry Players
Genfit SA; Prometheus Laboratories Inc.; Siemens Medical Solutions USA Inc.; BioPredictive; Quest Diagnostics; AstraZeneca Plc.; Laboratory Corporation of America Holdings; Pfizer Inc.; Bristol-Myers Squibb Company; NGM Biopharmaceuticals Inc.; Gilead Sciences Inc.; Perspectum Diagnostics Ltd.; One Way Liver SL; Enterome SA; Echosens SA; Cisbio Bioassays SAS; Celerion Inc.; Xeptagen SpA; Boehringer Ingelheim GmbH Inc.; Exalenz Bioscience Ltd.; Novartis AG; Novo Nordisk A/S; Allergan PLC.; Glympse Bio; HistoIndex Pte Ltd; Cirius Therapeutics; Intercept Pharmaceuticals; Viking Therapeutics; Madrigal Pharmaceuticals; Galmed Pharmaceuticals; Conatus Pharmaceuticals; Immuron Ltd; Metacrine
Get The Full Global Non-Alcoholic Steatohepatitis Biomarkers Market Report
AIOps Non-Alcoholic Steatohepatitis Biomarkers Market Overview
Non-alcoholic steatohepatitis (NASH) is a type of liver inflammation and damage caused by a build-up of fat in the liver. NASH biomarkers are used as diagnostic tools to assess the severity of non-alcoholic steatohepatitis and to assess liver damage. This damages the liver cells and inflames the liver, which can result in cirrhosis (liver scarring) and liver failure. Biomarkers refer to a particular quality that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment.
Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2023 provides data on the global non-alcoholic steatohepatitis biomarkers market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The non-alcoholic steatohepatitis biomarkers market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.